Please login to the form below

Not currently logged in
Email:
Password:

PARP inhibitor

This page shows the latest PARP inhibitor news and features for those working in and with pharma, biotech and healthcare.

Lynparza could soon add first line ovarian use in Europe

Lynparza could soon add first line ovarian use in Europe

Also first PARP inhibitor launched in China. AstraZeneca and its marketing partner MSD are close to gaining an European Union approval for Lynparza in first line use of ovarian cancer. ... The drug has also become the first PARP inhibitor launched in

Latest news

More from news
Approximately 1 fully matching, plus 85 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    The PARP inhibitor drug prevents BRCA mutation-carrying cells from repairing themselves, causing them to die. ... KUDOS had discovered olaparib, the first-in- class PARP inhibitor, which Galbraith’s team developed and brought to market as Lynparza.

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    for Lynparza, the first in class PARP inhibitor now approved in ovarian and breast cancers.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... 540. MEI Pharma (US). Helsinn (CH). Licence. Pracinostat, phase III-ready HDAC inhibitor for treatment of acute

  • Deal Watch April 2016 Deal Watch April 2016

    3, 340. Nimbus Apollo (US). Gilead (US). Company acquisition. Phase I Acetyl-CoA Carboxylase (ACC) inhibitor programme for live disease. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP inhibitor in clinical phase for

  • Pharma deals in August 2015 Pharma deals in August 2015

    Looking at another combination, AstraZeneca entered into a clinical trial collaboration this time with durvalumab in combination with Mirati Therapeutics' investigational spectrum-selective histone deacetylase (HDAC) inhibitor, mocetinostat.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics